or the pharmaceutical industry, the proposed tax reform might be spelled this way: G-I-F-T.

After years of grousing about the tax code, drug makers stand to benefit substantially from the changes the Trump administration is seeking. In fact, to a great extent, the plan that the White House is proposing appears to check off a few key items on an industry wish list, according to one tax expert.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.